Literature DB >> 24632291

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.

Francis W Hunter1, Jagdish K Jaiswal1, Daniel G Hurley2, H D Sarath Liyanage1, Sarah P McManaway1, Yongchuan Gu1, Susan Richter1, Jingli Wang1, Moana Tercel3, Cristin G Print2, William R Wilson3, Frederik B Pruijn4.   

Abstract

The nitro-chloromethylbenzindoline prodrug SN29428 has been rationally designed to target tumour hypoxia. SN29428 is metabolised to a DNA minor groove alkylator via oxygen-sensitive reductive activation initiated by unknown one-electron reductases. The present study sought to identify reductases capable of activating SN29428 in tumours. Expression of candidate reductases in cell lines was modulated using forced expression and, for P450 (cytochrome) oxidoreductase (POR), by zinc finger nuclease-mediated gene knockout. Affymetrix microarray mRNA expression of flavoreductases was correlated with SN29428 activation in a panel of 23 cancer cell lines. Reductive activation and cytotoxicity of prodrugs were measured using mass spectrometry and antiproliferative assays, respectively. SN29428 activation under hypoxia was strongly attenuated by the pan-flavoprotein inhibitor diphenyliodonium, but less so by knockout of POR suggesting other flavoreductases contribute. Forced expression of 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), as well as POR, increased activation of SN29428 in hypoxic HCT 116 cells. SN29428 activation strongly correlated with expression of POR and also FAD-dependent oxidoreductase domain containing 2 (FOXRED2), in cancer cell lines. This association persisted after removing the effect of POR enzyme activity using first-order partial correlation. Forced expression of FOXRED2 increased SN29428 activation and cytotoxicity in hypoxic HEK293 cells and also increased activation of hypoxia-targeted prodrugs PR-104A, tirapazamine and SN30000, and increased cytotoxicity of the clinical-stage prodrug TH-302. Thus this study has identified three flavoreductases capable of enzymatically activating SN29428, one of which (FOXRED2) has not previously been implicated in xenobiotic metabolism. These results will inform future development of biomarkers predictive of SN29428 sensitivity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FOXRED2; Hypoxia-targeting prodrug; NitroCBI; PR-104; TH-302; Tirapazamine

Mesh:

Substances:

Year:  2014        PMID: 24632291     DOI: 10.1016/j.bcp.2014.03.001

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.

Authors:  Cho Rong Hong; Sunali Y Mehta; H D Sarath Liyanage; Sarah P McManaway; Ho H Lee; Jagdish K Jaiswal; Gib Bogle; Moana Tercel; Frederik B Pruijn; William R Wilson; Kevin O Hicks
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-10       Impact factor: 3.333

2.  KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.

Authors:  Ádám Nagy; Lőrinc Sándor Pongor; András Szabó; Mariacarmela Santarpia; Balázs Győrffy
Journal:  Int J Cancer       Date:  2016-11-23       Impact factor: 7.396

3.  Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.

Authors:  Linda Spiegelberg; Ruud Houben; Raymon Niemans; Dirk de Ruysscher; Ala Yaromina; Jan Theys; Christopher P Guise; Jeffrey B Smaill; Adam V Patterson; Philippe Lambin; Ludwig J Dubois
Journal:  Clin Transl Radiat Oncol       Date:  2019-01-18

Review 4.  Therapeutic targeting of the hypoxic tumour microenvironment.

Authors:  Dean C Singleton; Andrew Macann; William R Wilson
Journal:  Nat Rev Clin Oncol       Date:  2021-07-29       Impact factor: 66.675

Review 5.  Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.

Authors:  Francis W Hunter; Bradly G Wouters; William R Wilson
Journal:  Br J Cancer       Date:  2016-04-12       Impact factor: 7.640

Review 6.  Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions.

Authors:  Guyue Cheng; Wei Sa; Chen Cao; Liangliang Guo; Haihong Hao; Zhenli Liu; Xu Wang; Zonghui Yuan
Journal:  Front Pharmacol       Date:  2016-03-21       Impact factor: 5.810

Review 7.  Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.

Authors:  Roger M Phillips
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-25       Impact factor: 3.333

Review 8.  How Are Proteins Reduced in the Endoplasmic Reticulum?

Authors:  Lars Ellgaard; Carolyn S Sevier; Neil J Bulleid
Journal:  Trends Biochem Sci       Date:  2017-11-15       Impact factor: 13.807

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.